BRPI0607326A2 - composição de vacina, variante de peptìdeo de survivina, uso da referida composição, kit em partes e medicamento - Google Patents

composição de vacina, variante de peptìdeo de survivina, uso da referida composição, kit em partes e medicamento

Info

Publication number
BRPI0607326A2
BRPI0607326A2 BRPI0607326-3A BRPI0607326A BRPI0607326A2 BR PI0607326 A2 BRPI0607326 A2 BR PI0607326A2 BR PI0607326 A BRPI0607326 A BR PI0607326A BR PI0607326 A2 BRPI0607326 A2 BR PI0607326A2
Authority
BR
Brazil
Prior art keywords
composition
vaccine
kit
parts
medicament
Prior art date
Application number
BRPI0607326-3A
Other languages
English (en)
Inventor
Mads Hald Andersen
Original Assignee
Survac Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Survac Aps filed Critical Survac Aps
Publication of BRPI0607326A2 publication Critical patent/BRPI0607326A2/pt
Publication of BRPI0607326B1 publication Critical patent/BRPI0607326B1/pt
Publication of BRPI0607326B8 publication Critical patent/BRPI0607326B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçãO DE VACINA, VARIANTE DE PEPTìDEO DE SURVIVINA, USO DA REFERIDA COMPOSIçãO, KIT EM PARTES E MEDICAMENTO. A presente invenção refere-se a uma vacina terapêutica compreendendo um ou mais fragmentos de polipeptídeo de Survivina. A vacina pode ser usada para o tratamento profilático, de melhora e/ou curativo de, por exemplo, doenças de câncer. A invenção refere-se ainda a métodos de tratamento de combinação.
BRPI0607326A 2005-02-04 2006-02-03 composição de vacina, uso da referida composição e kit em partes BRPI0607326B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200500173 2005-02-04
DKPA200500173 2005-02-04
US65075105P 2005-02-07 2005-02-07
US60/650,751 2005-02-07
PCT/DK2006/000061 WO2006081826A2 (en) 2005-02-04 2006-02-03 Survivin peptide vaccine

Publications (3)

Publication Number Publication Date
BRPI0607326A2 true BRPI0607326A2 (pt) 2009-09-01
BRPI0607326B1 BRPI0607326B1 (pt) 2021-01-19
BRPI0607326B8 BRPI0607326B8 (pt) 2021-05-25

Family

ID=39042995

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607326A BRPI0607326B8 (pt) 2005-02-04 2006-02-03 composição de vacina, uso da referida composição e kit em partes

Country Status (15)

Country Link
US (1) US20110091489A1 (pt)
EP (3) EP2329841A1 (pt)
JP (2) JP2008528643A (pt)
KR (1) KR20070108536A (pt)
CN (3) CN103143004A (pt)
AU (1) AU2006209951B2 (pt)
BR (1) BRPI0607326B8 (pt)
CA (1) CA2593714C (pt)
DK (1) DK1853305T3 (pt)
ES (1) ES2523172T3 (pt)
MX (1) MX2007009219A (pt)
PL (1) PL1853305T3 (pt)
RU (1) RU2396088C2 (pt)
WO (1) WO2006081826A2 (pt)
ZA (1) ZA200705943B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342093B2 (en) 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
WO2008116468A2 (en) * 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
WO2009003493A2 (en) * 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
EP2254592B1 (en) * 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
EP3320912B1 (en) 2008-04-17 2021-03-31 IO BIOTECH ApS Indoleamine 2, 3-dioxygenase based immunotherapy
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
FR2955775B1 (fr) * 2010-02-01 2012-05-04 Seppic Sa Adjuvant pour la preparation de compositions vaccinales destinees a la prevention contre les coccidioses
FR2955776A1 (fr) * 2010-02-01 2011-08-05 Seppic Sa Utilisation d'une huile minerale specifique pour la fabrication d'un nouveau adjuvant
SMT202100545T1 (it) 2012-05-16 2021-11-12 Stemline Therapeutics Inc Vaccini contro il cancro mirati alle cellule staminali cancerose
CA2908042C (en) * 2013-03-27 2023-01-31 Immunovaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
AU2014365888B2 (en) * 2013-12-16 2018-12-06 Merck Patent Gmbh Survivin-directed cancer vaccine therapy
WO2016109880A1 (en) 2015-01-06 2016-07-14 Immunovaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
CN108430505A (zh) 2015-11-18 2018-08-21 免疫疫苗技术有限公司 包括聚肌胞苷酸多核苷酸佐剂和基于脂质的佐剂的辅助系统以及无水疫苗组合物
TWI628189B (zh) * 2016-02-23 2018-07-01 財團法人國家衛生研究院 脂質化存活素（ｓｕｒｖｉｖｉｎ）及其用以預防及治療癌症之用途
LT3429618T (lt) 2016-03-16 2024-05-10 Amal Therapeutics Sa Imuninės sistemos patikros taško moduliatoriaus ir komplekso, apimančio į ląsteles prasiskverbiantį peptidą, krovinį ir tlr peptido agonistą, derinys, skirtas naudoti medicinoje
WO2018055060A1 (en) 2016-09-21 2018-03-29 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer
CN107228894B (zh) * 2017-01-24 2019-03-19 浙江海隆生物科技有限公司 一种油乳剂蛋白亚单位疫苗中蛋白含量和纯度的检测方法及其应用
CA3054861A1 (en) 2017-03-03 2018-09-07 Treos Bio Zrt Peptide vaccines
JP6993677B2 (ja) * 2017-11-08 2022-01-13 学校法人日本医科大学 犬におけるがんの予防、がんの治療またはがんの転移の予防のためのがんペプチドワクチン
JP2021508475A (ja) * 2017-12-28 2021-03-11 グリットストーン オンコロジー インコーポレイテッド 共有抗原を標的とする抗原結合タンパク質
MA53543A (fr) 2018-09-04 2021-07-14 Treos Bio Ltd Vaccins peptidiques
CA3119910A1 (en) * 2018-11-19 2020-05-28 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
EP3898666A2 (en) 2018-12-17 2021-10-27 Immudex ApS Panel comprising borrelia mhc multimers
CN115477686B (zh) * 2022-09-22 2024-01-30 北海黑珍珠海洋生物科技有限公司 一种具有美白功效的珍珠贝活性肽及其应用
WO2024186646A1 (en) 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making lipid adjuvanted compositions
WO2024186623A1 (en) 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making dried pharmaceutical compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
AU679902B2 (en) * 1992-09-30 1997-07-17 Ohio State University Research Foundation, The Vaccines and antigenic conjugates
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
KR100645448B1 (ko) 1996-11-20 2006-11-13 예일 유니버시티 세포 아폽토시스를 저해하는 설바이빈 단백질 및 이를 조절하는 방법
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US20030104570A1 (en) * 2000-06-26 2003-06-05 Cabezon Silva Teresa Elisa Virginia Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
DK1333850T3 (da) * 2000-10-20 2008-12-01 Genetics Inst Anvendelse af IL-13-inhibitorer til behandling af tumorer
JP2002365286A (ja) * 2000-11-13 2002-12-18 Kyogo Ito 細胞性免疫検出法およびその医薬への応用
JP4780540B2 (ja) * 2001-03-23 2011-09-28 北海道公立大学法人 札幌医科大学 サバイビン由来癌抗原ペプチド
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US20040210035A1 (en) * 2002-01-30 2004-10-21 Straten Eivind Per Thor Survivin-derived peptides and use thereof
US6780121B2 (en) * 2002-09-09 2004-08-24 Paul J. Herber Golf club head construction
ES2538486T3 (es) * 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
US7221826B2 (en) * 2002-10-08 2007-05-22 Tdk Corporation Spot-size transformer, method of producing spot-size transformer and waveguide-embedded optical circuit using spot-size transformer
NZ540735A (en) * 2002-12-02 2008-08-29 Resistentia Pharmaceuticals Ab Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-C5 amino acid segment and a non-self amino acid segment
US20060217297A1 (en) * 2003-01-15 2006-09-28 Haruo Sugiyama Dimerized peptide
ES2443582T3 (es) * 2003-06-27 2014-02-19 International Institute Of Cancer Immunology, Inc. Método para diagnosticar el cáncer que comprende la medición de las células precursoras de CTL específicos de WT1
US7842294B2 (en) * 2003-11-19 2010-11-30 Survac Aps Proteins belonging to the Bcl-2 family and fragments thereof, and their use in cancer patients

Also Published As

Publication number Publication date
WO2006081826A2 (en) 2006-08-10
CN103143004A (zh) 2013-06-12
CA2593714A1 (en) 2006-08-10
CN101111260B (zh) 2013-03-20
RU2396088C2 (ru) 2010-08-10
EP2329841A1 (en) 2011-06-08
JP2008528643A (ja) 2008-07-31
RU2007133103A (ru) 2009-03-10
EP1853305B1 (en) 2014-08-20
HK1112367A1 (en) 2008-08-29
AU2006209951B2 (en) 2011-04-14
ES2523172T3 (es) 2014-11-21
EP2329840A1 (en) 2011-06-08
CA2593714C (en) 2013-09-10
AU2006209951A1 (en) 2006-08-10
JP2012149101A (ja) 2012-08-09
ZA200705943B (en) 2008-12-31
WO2006081826A3 (en) 2007-02-15
DK1853305T3 (en) 2014-12-01
PL1853305T3 (pl) 2015-02-27
BRPI0607326B8 (pt) 2021-05-25
US20110091489A1 (en) 2011-04-21
CN103169958A (zh) 2013-06-26
CN101111260A (zh) 2008-01-23
BRPI0607326B1 (pt) 2021-01-19
MX2007009219A (es) 2008-01-16
KR20070108536A (ko) 2007-11-12
EP1853305A2 (en) 2007-11-14
JP5631357B2 (ja) 2014-11-26

Similar Documents

Publication Publication Date Title
BRPI0607326A2 (pt) composição de vacina, variante de peptìdeo de survivina, uso da referida composição, kit em partes e medicamento
BR112019000598A2 (pt) rna para terapia de câncer
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
CR9348A (es) Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112012018947B1 (pt) anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica
BRPI0410503B8 (pt) composição tópica e uso da composição
BR112012012918A8 (pt) Agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112015009037A2 (pt) composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
BR112012015202A2 (pt) "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes".
WO2007059979A3 (en) Allergy treatment by epicutaneous allergen administration
BRPI0415755A (pt) antagonistas do receptor b1 de bradiquinina
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
BR112013018365A2 (pt) "peptídeos derivados da lactoferrina humana, uso dos mesmos e composição farmacêutica"
HRP20110724T1 (hr) Smjese koje sadrže peptide mijelinskog bazičnog proteina i njihova medicinska uporaba
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/02/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF